Machine Learning for Personalized Cancer Care: Director’s Seminar Series |
On June 5, 2024 at 12:00 p.m., Adam Yala, PhD will present “Machine Learning for Personalized Cancer Care” for this session of the Distinguished Scientist Director's Seminar Series.
|
Expanding Immunotherapy Efficacy by Understanding Mechanisms of Response versus Resistance |
On July 11, 2024 at 4:00 p.m., Thomas F. Gajewski, MD, PhD will present “Expanding Immunotherapy Efficacy by Understanding Mechanisms of Response versus Resistance” for this session of the Distinguished Scientist Director’s Seminar Series.
|
|
|
Laura Schuettpelz, MD, PhD |
June 4, 2024 | 3:00 p.m. to 4:00 p.m.
Sanford Consortium for Regenerative Medicine and Zoom
|
Cancer Control Work in Progress (WIP) Series |
June 5, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
June 12, 2024 | 12:00 p.m. to 1:00 p.m.
Leichtag Biomedical Research Building, Room 107 and Zoom
|
June 14, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
|
|
Moores Speed Mentoring Workshop |
Thursday, June 13, 2023 | 1:00 p.m. to 2:00 p.m.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
|
|
|
Single-cell multiplex chromatin and RNA interactions in ageing human brain |
Sheng Zhong, PhD (Structural and Functional Genomics)
|
|
|
| Peptide-driven proton sponge nano-assembly for imaging and triggering lysosome-regulated immunogenic cancer cell death |
Nicole F. Steinmetz, PhD (Solid Tumor Therapeutics), Tariq M. Rana, PhD (Solid Tumor Therapeutics), and Jesse Jokerst, PhD (Solid Tumor Therapeutics)
|
|
|
| Many paths lead to immunology |
Silvio Gutkind, PhD (Cancer Biology and Signaling)
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
D419CR00030: A Phase IIIb Single Arm, Open-label, Multi-centre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma (SIERRA) |
PI: Adam Burgoyne, MD, PhD
NCT: NCT05883644
|
MVT-601-058: A Multi-Center, Prospective, Observational Study of Patients Being Treated with ORGOVYX |
PI: Rana McKay, MD
NCT: NCT05467176
|
IMM1104-101: A Phase I/IIa, Open-Label, Multicenter, Nonrandomized, Safety and Antitumor Activity Study of IMM1104, a Novel Oral Dual MEK1/2 Inhibitor in Participants with Previously Treated RAS-Mutated Advanced or Metastatic Solid |
PI: Peter Vu, MD
NCT: NCT05585320
|
Pro00110628: A Randomized Surgical Window of Opportunity Study with Dose Escalation to Evaluate Whether Oral Fluoxetine Can Induce Cytotoxic Lysosomal Stress and Enhance Temozolomide Efficacy in Clinical Glioma |
PI: David Piccioni, MD, PhD
NCT: NCT05634707
|
P-CD19CD20-ALLO1-001: Open-Label, Multicenter, Phase I Study to Assess the Safety of PCD19CD20ALLO1 in Subjects with Selected Relapsed/Refractory B-cell Malignancies |
PI: Carolyn Mulroney, MD
NCT: NCT06014762
|
| |
COMMUNITY OUTREACH AND ENGAGEMENT (COE) |
Reimagining Community Engagement and Equity in Cancer: A Virtual Conversation with Two Cancer Leaders |
In advance of Juneteenth, a national celebration of emancipation and equity, join ACCC President Dr. Nadine J. Barrett and AACI President Dr. Robert A. Winn in a discussion about their shared organizational goal to advance equitable cancer care. What will it take for the cancer community to effect real change? Learn about the science behind outreach engagement and how you can contribute in your community. Chat live with ACCC and AACI Executive Directors, Christian G. Downs and Jennifer W. Pegher, who will answer questions about this new ACCC-AACI partnership.
|
|
|
|
